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MinireviewDiverse Targets for Intervention during
Inflammatory and Neurodegenerative
Phases of Multiple Sclerosis
tified in MS susceptibility (Haines et al., 1996). This re-
gion contains the genes that encode the highly polymor-
phic human leukocyte antigen (HLA) D molecules used
to present peptide antigens to CD4 T cells. Individuals
with the HLA-DR2 (DRB*1501, DQB*0602) allele carry a
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3- to 4-fold risk for MS. Other genes within the HLASciences
complex, including tumor necrosis factor (TNF)-, com-Beckman Center for Molecular Medicine
ponents of the complement cascade, and myelin oligo-Stanford University
dendrocyte glycoprotein (MOG), are also involved in MSStanford, California 94305
pathogenesis. However, genes outside the HLA com-
plex also contribute to MS pathogenesis. In fact, ge-
nome-based studies of multiplex MS families (more thanMultiple sclerosis (MS) is an autoimmune central ner-
one family member affected) indicate that 10 to 15 cho-vous system (CNS) demyelinating disease that causes
mosomal loci contribute to MS susceptibility. Multiplerelapsing and chronic neurologic impairment. Recent
genes acting in concert may elevate the risk for MS.observations have altered certain traditional concepts
Myelin-Specific CD4 T Cells Initiateregarding MS pathogenesis. A greater diversity of cell
CNS Inflammationtypes and molecules involved in MS is now evident.
Evidence indicates that myelin-specific T cells partici-While remyelination can occur during the early inflam-
pate in the initial phase of MS. CD4 T cells specific formatory phase when damage may be reversible, it is
either MOG, myelin basic protein (MBP), or proteolipo-impaired in the later stages, which involve axonal
protein (PLP), three candidate CNS autoantigens, candeath. These observations have important therapeutic
induce experimental autoimmune encephalomyelitisimplications.
(EAE), an inflammatory CNS demyelinating disease
model for MS. Lymphocyte activation is required for
initial CNS entry. It is likely that an encounter with aMultiple sclerosis (MS) is the most common CNS demy-
microbe causes this activation, via both the innate andelinating disease, affecting 350,000 individuals in North
adaptive immune systems. Microbes containing non-America and more than 1.1 million worldwide. MS is
coding CpG sequences trigger innate immunity and leadmultiphasic (Steinman, 2001). Approximately 85% of in-
to secretion of proinflammatory mediators like interferondividuals begin with relapsing-remitting MS, a form
(IFN)-. Microbial organisms can also activate T cellscharacterized by attacks (exacerbations) of neurologic
via the adaptive immune system, through the T cell re-deficits with intervening periods of relative clinical stabil-
ceptor. Microbial pathogens share many conservedity. After 10 years, half of these individuals enter a sec-
structural gene and protein sequences with humans.ondary progressive phase, with persistent and advanc-
Thus, invading organisms can activate lymphocytes thating impairment. Another 10% of individuals, usually
are crossreactive to self-antigens, a process called “mo-somewhat older, have an insidious “primary” progres-
lecular mimicry.” Epstein-Barr virus, herpesvirus 6, mea-sive course from onset with few, if any, exacerbations.
sles, and papilloma virus are examples of viruses thatMS is considered to have an autoimmune basis. Women
contain shared sequences with myelin proteins. MS re-are affected at least twice as often as men, which is
lapses are often associated with microbial infections.characteristic of other autoimmune diseases, such as
Several discrete steps are involved in CNS entry and
rheumatoid arthritis or systemic lupus erythematosus,
initial inflammation (Figure 1). Activated T cells must
which also have a female gender bias.
penetrate the blood-brain barrier, which is composed
Both genetic and environmental factors contribute to of a specialized nonfenestrated capillary endothelium.
MS susceptibility. The prevalence varies between 50 to Activated proinflammatory (Th1) cells secrete IFN- and
100 per 100,000 in high-risk regions, which include the TNF-, cytokines that induce expression of vascular cell
northern United States and the Scandinavian countries, adhesion molecule (VCAM) on inflamed endothelium. Acti-
to less than 5 per 100,000 in Japan and Africa. Individu- vated T cells upregulate very late antigen (VLA)-4, the
als that migrate from high-risk to low-risk regions, or ligand for VCAM-1, as well as other adhesion molecules
vice versa, after adolescence carry their native risk for (selectins) that permit binding and transmigration
contracting MS, suggesting that exposure to an environ- through the endothelium. Antibody blockade of the in-
mental factor, possibly one of several different viruses, teraction of VLA-4 with VCAM-1 was effective in preven-
during childhood or adolescence contributes to MS sus- tion and reversal of relapsing EAE. A phase II trial dem-
ceptibility. Genetic studies have shown that the risk of onstrated that anti-VLA-4 antibodies reduced the
developing MS is elevated 10- to 20-fold in first-degree frequency of MS relapses and the mean number and
relatives of individuals with MS and that the concor- volume of new lesions on brain MRI scans (Miller et
dance rate among monozygotic (identical) twins is 30%– al., 2003). IFN-, an approved treatment for relapsing-
35%, but only 2%–5% in dizygotic (fraternal) twins. remitting MS, also prevents upregulation of VLA-4 and
Chromosome 6p21 is one locus most consistently iden- VCAM-1.
Before entering CNS parenchyma, activated T cells
must penetrate through an extracellular matrix com-*Correspondence: zamvil@ucsf.neuroimmunol.org
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Figure 1. The Inflammatory Phase of MS
In EAE, T lymphocytes gain access to the
CNS via their 4 integrins, recognizing VCAM
on the blood vessel wall. The T cells diaped-
ese through the endothelium, using matrix
metalloproteases to cleave collagen IV in the
extracellular matrix. Once within the CNS,
they release inflammatory cytokines. The B
cell and the mast cell also contribute to pa-
thology. Complement plus antibody leads to
activation of membrane attack complexes
which attack the myelin sheath. EAE can be
blocked by an 4 integrin antibody. Antegren,
which recognizes human 4 integrin, has
shown promise in phase II trials in MS. Statins
and altered peptide ligands can interfere with
the recognition of myelin fragments by induc-
ible MHC class II in the CNS. Antihistamines
and platelet activating receptor antagonists
can block mast cell activity in EAE.
posed of type IV collagen. Matrix metalloproteases MMPs and other proteolytic enzymes, including cathep-
sins, a family of cysteine and aspartyl proteases, are(MMPs) are a family of proteolytic enzymes that degrade
this basement membrane. MMPs also have TNF- con- secreted by microglia in response to IFN- activation
and participate in processing of myelin proteins. Proteo-vertase activity and cleave membrane-bound TNF- to
its soluble form. MMP-9 (Gelatinase B), which has an lytic 13-16 amino acid peptide fragments that bind MHC
class II molecules on resident CNS APC are recognizedimportant role in basement membrane degradation, is
secreted by activated, myelin-specific T cell clones from by the antigen-specific T cell receptors expressed on
myelin-specific CD4 T cells. This causes de novo CNSMS patients and encephalitogenic murine T cell clones.
MMP-9 is also detectable in endothelial cells, pericytes, T cell activation and further secretion of IFN-, ampli-
fying myelin autoantigen recognition and T cell activa-and astrocytes in MS lesions, as well as in spinal fluid
from MS patients. T cell penetration of extracellular ma- tion. IFN-, which inhibits IFN--inducible class II ex-
pression, may also suppress antigen recognition bytrix can be blocked by tissue inhibitors of matrix metallo-
proteases (TIMPs), a family of proteins that bind and pathogenic T cells. One goal in MS therapy has been
to develop agents that selectively inhibit pathogenicprevent MMP activity. IFN- also inhibits MMP activity
by T cells, providing another mechanism for its beneficial myelin-reactive T cells. Altered peptide ligands (APL),
which are synthetic mutant myelin peptides that areeffects. Considerable effort is being devoted to the de-
velopment and testing of other MMP inhibitors. designed to alter antigen/MHC recognition and promote
T cell secretion of antiinflammatory (Th2) cytokines areWhile lymphocyte activation facilitates CNS entry, an-
tigen-specific recognition is not required at this stage. being tested in relapsing-remitting MS (Kappos et al.,
2000). Glatiramer acetate (Copaxone, Cop-1), a medica-However, myelin recognition is required for initial CNS
inflammation. Antigen recognition by CD4 T cells re- tion used in treatment of relapsing-remitting MS, is a
synthetic random copolymer composed of tyrosine, glu-quires expression of MHC class II molecules on antigen-
presenting cells (APC), yet the normal CNS is nearly tamic acid, alanine, and lysine that appears to preferen-
tially affect T cells specific for CNS autoantigens, possi-devoid of class II expression. Through secretion of
IFN-, which is a potent stimulator of class II expression bly in a manner similar to APL (Duda et al., 2000).
T Cells, B Cells, and Myelin-Specificon resident CNS APC including microglia and astro-
cytes, it is thought that Th1 cells drive this stage of Autoantibodies Promote CNS Demyelination
Most MS and EAE studies have focused on the role ofpathogenesis (Slavin et al., 2001). IFN- secretion is
driven by osteopontin, a cytokine produced by neurons myelin-specific CD4 T cells. Other T cell subtypes can
participate in CNS demyelination. Clonal expansions ofand glia in inflamed CNS (Chabas et al., 2001) (Figure
1). IFN- and its associated downstream genes are in- CD8 T cells also occur in demyelinating MS and EAE
lesions. Two groups reported that myelin-specific CD8creased in MS lesions (Lock et al., 2002). Intact myelin
proteins are not recognized by T cells but undergo pro- T cells, which recognize antigen in association with MHC
class I molecules, could induce EAE (Huseby et al., 2001;teolytic processing into peptide fragments by APC be-
fore binding MHC class II molecules and presentation Sun et al., 2001). The pathology was not the same as in
EAE induced by CD4 T cells, but in some ways it wasto CD4 T cells. It was observed that mutant mice con-
taining APC that expressed class II molecules and could more reminiscent of MS. CD8 T cells may have more
potential CNS targets than CD4 T cells. For example,present myelin peptide but not process native (intact)
myelin protein were completely resistant to EAE (Slavin oligodendrocytes can upregulate MHC class I but not
class II molecules. While those two studies have sparkedet al., 2001), indicating that myelin peptides are not nor-
mally exposed in normal CNS without processing. wide interest in elucidating the role of CD8 T cells in
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MS pathogenesis, it should be recognized that in general demyelinating MS lesions, Lucchinetti and colleagues
distinguished four distinct histologic patterns (Lucchi-CD8 T cell expansion requires help from CD4 T cells
(Stuve et al., 2002), and elimination of CD8 T cells has netti et al., 2000). The first two patterns were similar and
characterized by perivenular demyelination with pre-caused more EAE relapses. It is likely that therapies
targeting CD8 myelin-specific T cells will also need to dominance of macrophages and T cells within inflamma-
tory lesions. IgG deposition and complement distin-suppress the activity of CD4 T cells. Natural killer T
(NKT) cells, although much less abundant than CD4 or guished the second, most common, pattern and both of
these patterns resembled lesions in EAE. DemyelinationCD8 T cells, may have a role in CNS demyelination.
Unlike conventional T cells that recognize protein anti- was not perivenular in the two other patterns. While
demyelinating lesions of these latter two patterns con-gens, NKT cells recognize glycolipids, major constit-
uents of myelin. NKT cells bear an invariant T cell recep- tained T cells and macrophages, IgG and complement
were absent. These two patterns were also character-tor and recognize -galactoceramide, the prototype
glycolipid in the context of a nonpolymorphic MHC class ized by loss of oligodendrocytes, suggesting a primary
oligodendrogliopathy. Interestingly, lesions within aI-like molecule known as “CD1d.” One study showed that
an analog of -galactoceramide suppressed clinical EAE given individual were homogeneous. However, most tis-
sue samples in this study were obtained by needle biop-(Miyamoto et al., 2001), suggesting that “altered lipid
ligands” might also be an attractive means for interven- sies. Larger scale autopsy studies revealed consider-
able heterogeneity even within a single focus, with ation in MS.
Once the integrity of the blood-brain barrier is com- spectrum of activity ranging from acute inflammation to
gliosis (Lock et al., 2002). In comparison of specimenspromised during initial CNS inflammation, other mono-
nuclear cells, including B cells and macrophages, pene- between individuals, Luchinetti and colleagues ob-
served marked heterogeneity. Pathologic heterogeneitytrate into the CNS. B cells may have a dual role. B
cells serve as APC and may expose additional myelin clearly has profound implications for MS treatment.
Demyelination in early MS is not necessarily perma-autoantigens, permitting the immune response to diver-
sify. Myelin-specific B cells that differentiate into plasma nent. Remyelination by oligodendrocytes has been well
documented in relapsing-remitting MS. While myelin iscells secrete antibodies (Abs) (Figure 1), which are also
detected in active demyelinating lesions in MS and EAE the primary target for damage in early MS, axonal degen-
eration accumulates in chronic MS. Axonal loss, which(Genain et al., 1999; Warren et al., 1995). While passive
transfer of myelin-specific Abs alone does not initiate is irreversible, is detected within demyelinating lesions
as well as in normal-appearing white matter, likely sec-CNS inflammation or demyelination, they do promote
demyelination once T cells establish CNS inflammation. ondary to Wallerian degeneration. Axonal degeneration
correlates with both permanent disability and brain atro-A B cell-depleting monoclonal Ab is currently being
tested in MS. Activated components of the complement phy in advanced MS. One study identified the presence
of oligodendrocyte progenitors in chronic lesions, andcascade, including its terminal components, the “mem-
brane attack complex,” are also detected along nerve they appeared to interact with dystrophic naked axons
but were unable to remyelinate them (Chang et al., 2002).fibers in active demyelinating lesions and periplaque
white matter (Prineas et al., 2001). In some cases, com- These results suggest that axons in chronic MS are not
receptive to remyelination and raise concern regardingplement components are detected without the presence
of IgG Ab, indicating that Ab-independent complement transplantation of oligodendrocyte precursors (Hohl-
feld, 2002). TGF-, which can be secreted by inflamma-activation also occurs and may promote demyelination
in a nonspecific manner. tory or glial cells during CNS demyelination, induces
astrocytes to produce jagged1, which binds the Notch1Mast cells are also present in MS lesions (Pedotti et
al., 2003). Analysis of mRNA from MS lesions revealed receptor expressed on oligodendrocyte precursors. As
a consequence of Notch-mediated signaling, oligoden-increased transcripts for several genes encoding mole-
cules traditionally associated with allergic responses drocyte precursors failed to extend processes and re-
place degenerating myelin. In contrast, one group ob-(Chabas et al., 2001; Pedotti et al., 2003). Histamine
receptors 1 and 2 (H2R) are present on inflammatory served migration of neural progenitor cells in EAE from
the subventricular zone (SVZ) to the olfactory bulb andcells in EAE brain lesions, and histamine receptor genes
confer susceptibility to EAE (Ma et al., 2002). Encephali- mobilization of progenitor cells in periventricular white
matter, a region frequently involved in MS (Picard-Rieratogenic Th1 cells express more H1R and less H2R than
Th2 cells. An H1R antagonist blocked EAE, and a PAFR et al., 2002). Progenitor cells in periventricular white
matter gave rise to oligodendrocytes and astrocytes,antagonist reduced the severity of EAE. EAE was attenu-
ated in mast cell-deficient mice. Taken together, these indicating the SVZ is a source of newly generated oligo-
dendrocytes that might promote remyelination.data reveal involvement of elements associated with
allergy in autoimmune demyelination. The role of mast During CNS inflammation, glutamate is released by
activated leukocytes and microglia. Glutamate excito-cells presents a challenge to our understanding of the
pathophysiology of these autoimmune disorders, pre- toxicity mediated by AMPA/kinate receptors causes
damage to neurons and oligodendrocytes. One AMPA/viously thought to be diametrically opposite to allergy.
Pathogenesis of demyelination must now be viewed as kinate antagonist suppressed clinical EAE (Pitt et al.,
2000). While treatment with this AMPA/kinate receptorencompassing elements of both Th1 and “allergic” re-
sponses: allergy and autoimmunity are not antipodal. antagonist did not alter CNS inflammation or prolifera-
tion by encephalitogenic T cells, treatment was associ-Pathologic Heterogeneity in MS
Just as there is heterogeneity in clinical MS, there is also ated with increased oligodendrocyte survival and re-
duced axonal loss. These observations underscore themarked histologic heterogeneity. In analysis of acute
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